Simponi and Skin atrophy - a phase IV clinical study of FDA data

Summary:

Skin atrophy is reported as a side effect among people who take Simponi (golimumab), especially for people who are female, 60+ old, have been taking the drug for 6 - 12 months also take Synthroid, and have Arthritis.

The phase IV clinical study analyzes which people have Skin atrophy when taking Simponi. It is created by eHealthMe based on reports of 86,103 people who have side effects when taking Simponi from the FDA, and is updated regularly.

What is Simponi?

Simponi has active ingredients of golimumab. It is often used in rheumatoid arthritis. eHealthMe is studying from 86,328 Simponi users. Check the latest studies of Simponi.

What is Skin atrophy?

Skin atrophy (wasting of skin) is found to be associated with 623 drugs and 718 conditions by eHealthMe. Check the latest studies of Skin atrophy.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 26, 2026

86,103 people reported to have side effects when taking Simponi.
Among them, 14 people (0.02%) have Skin atrophy.

Among these 14 people:

How long have people been on Simponi when they have Skin atrophy? *

What is the gender of people who have Skin atrophy when taking Simponi? *

female: 76.92 %
male: 23.08 %

What is the age of people who have Skin atrophy when taking Simponi? *

What are other drugs people take besides Simponi? *

What are other side effects people have besides Skin atrophy? *

Dry Skin: 5 people, 35.71%
Pain: 4 people, 28.57%
Cuts And Puncture Wounds: 4 people, 28.57%
Rashes (redness): 4 people, 28.57%
Joint Pain: 4 people, 28.57%
Itching: 3 people, 21.43%
Oropharyngeal Pain: 3 people, 21.43%
Cataract (clouding of the lens inside the eye): 3 people, 21.43%
Diarrhea: 2 people, 14.29%
Vulvovaginal Mycotic Infection (vulvovaginal fungal infection): 2 people, 14.29%

What are the existing conditions these people have? *

Arthritis (form of joint disorder that involves inflammation of one or more joints): 2 people, 14.29%
Urinary Tract Infection: 1 person, 7.14%
Tooth Abscess (pus formation in tooth): 1 person, 7.14%
Thyroid Diseases: 1 person, 7.14%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 1 person, 7.14%
Psoriasis (immune-mediated disease that affects the skin): 1 person, 7.14%
Oropharyngeal Pain: 1 person, 7.14%
Insomnia (sleeplessness): 1 person, 7.14%
High Blood Pressure: 1 person, 7.14%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Simponi and have Skin atrophy?

- Check whether Skin atrophy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Simponi:

Simponi (86,328 reports)

Skin atrophy treatments and more:

Skin atrophy (6,670 reports)

Browse all side effects of Simponi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Skin atrophy:

Skin atrophy (623 drugs)

Browse all the conditions that are associated with Skin atrophy:

Skin atrophy (718 conditions)

Related publications that referenced our studies

Azuma N, Matsui K, Hashimoto N, Yoshikawa T, Sano H, "Successful Switch to Golimumab for Eosinophilia and Skin Symptoms Related to Multiple Biologics in a Patient with Rheumatoid Arthritis", Internal Medicine, 2017 Jun .
Azuma N, Matsui K, Hashimoto N, Yoshikawa T, Sano H, "Successful Switch to Golimumab for Eosinophilia and Skin Symptoms Related to Multiple Biologics in a Patient with Rheumatoid Arthritis", Internal Medicine, 2017 Jun .

How the study uses the data?

The study uses data from the FDA. It is based on golimumab (the active ingredients of Simponi) and Simponi (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.